UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Annals of oncology, 2024-01, Vol.35 (1), p.77-90

2024

Volltextzugriff (PDF)

Underdetection and Undertreatment of Dyspnea in Critically Ill Patients

American journal of respiratory and critical care medicine, 2019-06, Vol.199 (11), p.1377-1384

2019

Volltextzugriff (PDF)

Underdetection and Undertreatment of Dyspnea in Critically Ill Patients

American journal of respiratory and critical care medicine, 2019-06, Vol.199 (11), p.1377-1384

2019

Volltextzugriff (PDF)

Safety and Effectiveness of Selexipag in Pediatric Pulmonary Hypertension: A Retrospective Multicenter Cohort Study

The Journal of pediatrics, 2024-12, Vol.275, p.114221, Article 114221

2024

Volltextzugriff (PDF)

P1.13A.03 MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S207-S207

2024

Volltextzugriff (PDF)

Peripheral Blood Cell Free DNA to Monitor Mutational Response in Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2017-05, Vol.98 (1), p.250-250

2017

Volltextzugriff (PDF)

P40.04 CNS Adverse Events and Survival in Patients with NSCLC Brain Metastases Treated With Concurrent Radiation and Immunotherapy

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1070-S1071

2021

Volltextzugriff (PDF)

PP01.44 Long-Term Survival and Outcomes by Race from the Phase I/II trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced NSCLC: HCRN LUN13-175

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.e29-e29

2023

Volltextzugriff (PDF)

P45.16 Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1092-S1092

2021

Volltextzugriff (PDF)

MO01.12 Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S20-S21

2021

Volltextzugriff (PDF)

P2.04-75 Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S738-S738

2019

Volltextzugriff (PDF)

P2.01-52 Clinical Characteristics and Outcomes in NSCLC Patients Associated with Very High PD-L1 Expression

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S659-S660

2019

Volltextzugriff (PDF)

P3.01-09 Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S870-S870

2018

Volltextzugriff (PDF)

FP14.08 Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S230-S231

2021

Volltextzugriff (PDF)

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)

Annals of oncology, 2020-09, Vol.31, p.S815-S816

2020

Volltextzugriff (PDF)

OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S873-S874

2021

Volltextzugriff (PDF)

P2.01-39 Can Benefit or Futility in Treating Advanced Nsclc Be Determined Early Using the LCSS 3-Item Global Index (3-IGI) PRO?

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S679-S680

2018

Volltextzugriff (PDF)

P1.01-67 Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC (HCRN LUN13-175): Outcomes by Nab-Paclitaxel Dose

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S385-S386

2019

Volltextzugriff (PDF)

Carboplatin/ nab -Paclitaxel and Pembrolizumab for Patients with Advanced Non–Small Cell Lung Cancer (NSCLC): Phase 1 Results

International journal of radiation oncology, biology, physics, 2017-05, Vol.98 (1), p.236-236

2017

Volltextzugriff (PDF)

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S321-S321

2018

Volltextzugriff (PDF)

P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S627-S627

2019

Volltextzugriff (PDF)

Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

Annals of oncology, 2016-10, Vol.27, p.vi582-vi582

2016

Volltextzugriff (PDF)

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S216-S216

2019

Volltextzugriff (PDF)

OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1791-S1791

2017

Volltextzugriff (PDF)

Safety and Effectiveness of Selexipag in Pediatric Pulmonary Hypertension: A Retrospective Multi-Center Cohort Study

The Journal of pediatrics, 2024-08, p.114221

2024

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(76)
Buchkapitel
(1)

Sprache

Englisch
(77)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Underdetection and Undertreatment of Dyspnea in Critically Ill Patients

Underdetection and Undertreatment of Dyspnea in Critically Ill Patients

Safety and Effectiveness of Selexipag in Pediatric Pulmonary Hypertension: A Retrospective Multicenter Cohort Study

P1.13A.03 MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC

Peripheral Blood Cell Free DNA to Monitor Mutational Response in Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer

P40.04 CNS Adverse Events and Survival in Patients with NSCLC Brain Metastases Treated With Concurrent Radiation and Immunotherapy

PP01.44 Long-Term Survival and Outcomes by Race from the Phase I/II trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced NSCLC: HCRN LUN13-175

P45.16 Adverse Event Burden of Oral Tyrosine Kinase Inhibitors in EGFR and ALK Metastatic Non-Small Cell Lung Cancer

MO01.12 Association of Opioid Use with Survival in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitor Therapy

P2.04-75 Overall Survival by IDO1 and PD-L1 Expression in NSCLC Patients Receiving an Immune Checkpoint Inhibitor (ICI)

P2.01-52 Clinical Characteristics and Outcomes in NSCLC Patients Associated with Very High PD-L1 Expression

P3.01-09 Impact of Urban or Rural Residence on Overall Survival for Patients with Metastatic Non-Squamous NSCLC

FP14.08 Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)

OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

P2.01-39 Can Benefit or Futility in Treating Advanced Nsclc Be Determined Early Using the LCSS 3-Item Global Index (3-IGI) PRO?

P1.01-67 Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC (HCRN LUN13-175): Outcomes by Nab-Paclitaxel Dose

Carboplatin/ nab -Paclitaxel and Pembrolizumab for Patients with Advanced Non–Small Cell Lung Cancer (NSCLC): Phase 1 Results

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC

P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy

Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update

Safety and Effectiveness of Selexipag in Pediatric Pulmonary Hypertension: A Retrospective Multi-Center Cohort Study

Suchergebnisse filtern